Rheumatoid Arthritis is an autoimmune disease which causes the severe pain and inflammation of synovial membrane. For reducing the pain NSAIDs are given. Piroxicam is widely used in the Rheumatoid Arthritis to reduce the pain. Piroxicam is the ââ?¬Å?BCS class IIââ?¬Â Drug which has the dissolution rate limited bioavailability. Nanosponges are mostly used for the solubility enhancement of the low solubility drugs. Hence the aim of this study was to develop the nanosponge which increases the dissolution rate of the Piroxicam. Preliminary study was performed by melting point, FTIR and solubility study of the Piroxicam. Screening of cross-linking agent was confirmed by the solubility and FTIR study and Diphenyl Carbonate showed the desirable result hence it was selected for further study. Nanosponges were initially prepared by preparing Blank nanosponge by polymerization method by using the different weight ratio of Beta-cyclodextrin and Diphenyl carbonate. Then Drug was loaded into the Blank nanosponge. The Prepared Nanosponges were evaluated for drug loading capacity, In-vitro drug release study, Zeta Potential. The Optimized formulation was composed of the (1:5) ratio of the Ã?Ÿ-CD to DPC gave 76.36% Drug loading, 98.86% drug release, -25.4 mV Zeta-potential, 0.342 PDI. DSC was done to check complex between drug and nanosponge. SEM was done for the morphology. Gas chromatography was done to check unreacted amount of DPC Optimized in formulation.
Loading....